Saturday 17 October 2026
Export NNNN’s income statement to Excel — free account
Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
3.29
0.01
−0.30%
Follow NNNN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | — | — |
Altman Z-Score |
8,977.35 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
370.99 | 19.93 | 25.67 | 23.06 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
2.00 | (3.23) | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(17.30) | 0.00 | 0.00 | 0.00 |
EV/FCF |
(17.30) | 0.00 | 0.00 | 0.00 |
Quick Ratio |
177.19 | 7.41 | 11.65 | 6.14 |
Current Ratio |
344.45 | 10.71 | 15.86 | 9.88 |
Net Debt/EBITDA |
(2.06) | (5.89) | (4.94) | (0.85) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.35 | 0.47 | 0.45 | 0.00 |
Operating CF/Net income |
(1.05) | 0.88 | 0.40 | 0.44 |
Interest Coverage |
— | — | — | 1,274.45 |
| 27.05% | 14.83% | 16.47% | 0.00% | |
| 26.05% | 13.66% | 15.14% | 0.00% | |
ROIC |
19.75% | 22.96% | 23.89% | 164.32% |
Return on Tangible Assets |
21.24% | 14.12% | 15.27% | 79.89% |
Average Days of Receivables |
154.33 | 47.48 | 102.51 | 0.00 |
Research and Development Expense of Revenue |
2.33% | 5.55% | 2.01% | 0.85% |
Selling, General and Administrative Expense of Revenue |
18.20% | 41.98% | 18.85% | 9.21% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.20 | 0.19 | 0.31 | 235,447.00 |
Operating CF per Share |
(0.15) | 0.05 | 0.04 | 44,488.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.15) | 0.05 | 0.04 | 44,488.00 |
Cash per Share |
0.27 | 0.28 | 0.45 | 86,691.00 |
Shareholders Equity per Share |
0.69 | 0.41 | 0.69 | 125,470.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.69 | 0.41 | 0.69 | 125,470.00 |
Free Cash Flow |
(6.74) | 2.08 | 0.90 | 4.45 |
Working Capital |
30.16 | 16.80 | 14.76 | 12.53 |
Net Current Asset Value |
30.16 | 16.80 | 14.76 | 12.53 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Cash ROIC |
(16.02%) | 7.19% | 3.67% | 20.97% |
Accounts Receivable Turnover |
3.66 | 5.55 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 1.88 | 3.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 257.95 | 90.10 | 46.80 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 11.76 |
Average Receivables |
2.36 | 1.47 | — | — |
Average Payables |
— | 1.23 | 1.12 | — |
Average Assets |
24.58 | 17.37 | 14.89 | — |
Average Common Equity |
23.67 | 16.01 | 13.68 | — |
Columns are period end dates